FOR IMMEDIATE RELEASE

PlantForm to present at biotech roundtable in U.K.

Ontario biotech mission includes BioTrinity 2014 partnering and investment conference

GUELPH, Ont., May 12, 2014—Dr. Don Stewart, President and CEO of PlantForm Corporation, will present an overview of the company and its plant-based biopharmaceutical manufacturing platform at a roundtable discussion at the High Commission of Canada in London, England today. The roundtable is part of the Ontario biotech mission to the United Kingdom, organized by the Ontario Ministry of Economic Development, Trade and Employment.

The mission also includes participation in BioTrinity 2014, the European Biopartnering and Investment Conference, which takes place May 12-14.

“PlantForm is pleased to participate in this trade mission to raise awareness about our plant technology and its ability to significantly lower the cost of producing important antibody drugs for the treatment of cancer and other devastating diseases,” Stewart said.

PlantForm’s technology features a unique high-expression production system and the ability to produce fully human versions of biologic drugs from plants – two critical innovations that give the company a competitive edge over its big pharma and biotech competitors, Stewart said.

PlantForm Corporation’s pipeline includes three biosimilar (generic) monoclonal antibodies for cancer, six innovator antibodies for HIV/AIDS, and a novel protein drug designed to protect against nerve agent exposure. See a video introducing PlantForm or learn more about the company at www.plantformcorp.com.

-30-

For more information, please contact:

Don Stewart
President and CEO
don.stewart@plantformcorp.com
(416) 452-7242

Stacey Curry Gunn
Director of Communications
stacey.curry.gunn@plantformcorp.com
(519) 827-1131